Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

107 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-06-30

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the benefits of continuing celecoxib through six weeks of total knee arthroplasty recovery. This is a randomized, double blind study with a group of approximately 130 primary total knee patients. All patients will receive celecoxib throughout their hospitalization as per current minimally invasive total knee arthroplasty protocol. At the time of hospital discharge, participating patients will be randomly placed on either celecoxib 200mg twice a day or a placebo twice a day.

This study will determine if the continued use of celecoxib for six weeks after total knee arthroplasty hospitalization will further decrease narcotic consumption, improve knee range of motion, improve ambulatory ability, and improve patient satisfaction over patients receiving celecoxib only during the acute hospitalization.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Arthroplasty Inflammation Prophylaxis With Celecoxib

NCT00533247

Postoperative Pain

UNKNOWN NA

Safety of F14 Following Total Knee Replacement

NCT04860635

Analgesia

SUSPENDED PHASE2/PHASE3

Effect of Celecoxib Versus Placebo Before and After Knee Surgery on Overall Use of Analgesics After Surgery

NCT00633438

Arthroscopy

COMPLETED PHASE4

Celebrex Total Knee Arthroplasty Study

NCT00359151

Osteoarthritis Pain

TERMINATED PHASE4

Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery

NCT00633386

Arthroscopy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Management Function Minimally Invasive Total Knee Arthroplasty Celecoxib

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Celecoxib

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* having undergone a minimally invasive total knee by select surgeon
* voluntarily enrolled
* independent community ambulators
* only patients being discharged directly home

Exclusion Criteria

* celecoxib allergy or intolerence
* Renal insufficiency (defined as serum creatine level \>1.5 mg/dL or BUN level \>22mg/dL
* History of bleeding gastic or duodenal ulceration
* New York Heart Association Class III or IV Congestive Heart Failure
* Previous myocardial infarction or cerebralvascular event
* Severe inflammatory bowel disease
* Known coagulation abnormality or hepatic disease
* Chronic coumadin administration
* Refusal by primary or cardiac physician

Eligible Sex

ALL

Accepts Healthy Volunteers

No